3,7,8,2'-Tetrahydroxyflavone
3,7-Dihydroxyflavone
4'-Dimethylamino-7,8-dihydroxyflavone
7,3′-Dihydroxyflavone
7,8,2'-Trihydroxyflavone
7,8,3'-Trihydroxyflavone
7,8-Dihydroxyflavone
ABT-110
ALE-0540
AM7 (drug)
AMG-458
ANA-12
ANXA2
ASP-6294
ATC code L01
ATC code S01
AVE-1642
AZD-6918
Abciximab
Abelacimab
Abemaciclib
Acalabrutinib
Accelerated approval
Acetone
Adagrasib
Adipotide
Adrenomedullin
Aducanumab
Afatinib
Aflibercept
Age-related macular degeneration
Agerafenib
Alacizumab pegol
Alectinib
Alemtuzumab
Alirocumab
Allergic reactions
Alpelisib
Altiratinib
American Society of Health-System Pharmacists
Amitriptyline
Amivantamab
Amphiregulin
Amuvatinib
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Ancestim
Angiogenesis
Angiogenesis inhibitor
Angiopoietin 1
Angiopoietin 2
Angiopoietin 3
Angiopoietin 4
Angiopoietin receptor
Anti-amyloid drugs
Antigen
Antineoplastic
Anti–vascular endothelial growth factor therapy
Aprutumab
Aprutumab ixadotin
Artemin
Asciminib
Ascrinvacumab
Atezolizumab
Atezolizumab/hyaluronidase
Atherosclerosis
Aumolertinib
Australian Broadcasting Corporation
Avapritinib
Avelumab
Axatilimab
Axitinib
Axokine
BBC News Online
BMS-754807
BMS-777607
BNN-20
BNN-27
BRAF (gene)
Bapineuzumab
Baricitinib
Bcr-abl fusion protein
Becaplermin
Belantamab mafodotin
Bentracimab
Benzoic acid
Bermekimab
Betacellulin
Bevacizumab (data page)
Bimagrumab
Binimetinib
Bioavailability
Biological half-life
Biosimilar
Biosimilars
Bleeding
Blinatumomab
Blood clots
Blosozumab
Bococizumab
Bone
Bosutinib
Bowel perforation
Brain-derived neurotrophic factor
Breast cancer
Brentuximab vedotin
Brigatinib
Brolucizumab
Bruton's tyrosine kinase
Burosumab
C-Met
CAS Registry Number
CBC News
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
CE-245677
CH-7057288
CSPG5
Cabozantinib
Cancer
Cancer Drugs Fund
Cancer immunotherapy
Canertinib
Caplacizumab
Capmatinib
Carboplatin
Catumaxomab
Cediranib
Cemiplimab
Cenegermin
Cerebrolysin
Ceritinib
Cetuximab
ChEMBL
ChemSpider
Chemical formula
Chemotherapy
Chinese hamster ovary cell
Ciliary neurotrophic factor receptor
Circulatory system
Citrate
Cixutumumab
Clinical trial
Cobimetinib
Collateral circulation
Colon cancer
Colony-stimulating factor
Colorectal cancer
Committee for Medicinal Products for Human Use
Complementarity-determining region
Concizumab
Connective tissue growth factor
Copanlisib
Coronary artery disease
Cosibelimab
Crenezumab
Crenolanib
Crizotinib
Cyclotraxin B
DMAQ-B1
DS-6051
Dabrafenib
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Dapiclermin
Daratumumab
Dasatinib
Dehydroepiandrosterone
Dehydroepiandrosterone sulfate
Demcizumab
Denileukin diftitox
Denosumab
Deoxygedunin
Department of Health and Aged Care
Depatuxizumab
Depatuxizumab mafodotin
Deprenyl
Des(1-3)IGF-1
Dexamethasone
Dihexa
Dinutuximab beta
Diosmetin
Doi (identifier)
Domagrozumab
Donanemab
Dostarlimab
DrugBank
Drug nomenclature
Drugs.com
Duligotumab
Durvalumab
Dusigitumab
Duvelisib
EFNA1
EFNA2
EFNA3
EFNA4
EFNA5
EFNB1
EFNB2
EFNB3
EML4
EVT-901
Edrecolomab
Elotuzumab
Elranatamab
Emibetuzumab
Emicizumab
Encorafenib
Enfortumab vedotin
Enoticumab
Entrectinib
EpCAM
Epcoritamab
Ephrin
Epidermal growth factor
Epidermal growth factor receptor
Epigen
Epiregulin
Eptinezumab
ErbB
Erdafitinib
Erenumab
Erlotinib
Ersofermin
Ertumaxomab
Erythropoietin
Etaracizumab
European Medicines Agency
Everolimus
Evinacumab
Evolocumab
Exotoxin
Eye disease
FGF1
FGF10
FGF15/19
FGF17
FGF18
FGF19
FGF2
FGF20
FGF22
FGF23
FGF3
FGF4
FGF5
FGF6
FGF7
FGF8
FGF9
FX007
Faricimab
Fasinumab
Fedratinib
Fibroblast growth factor
Fibroblast growth factor receptor
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor 2
Fibroblast growth factor receptor 3
Fibroblast growth factor receptor 4
Ficlatuzumab
Figitumumab
Filgotinib
First-line therapy
First-line treatment
Fistula
Flanvotumab
Food and Drug Administration
Foretinib
Fosgonimeton
Fraunhofer Society
Fremanezumab
Frunevetmab
Fruquintinib
Fulranumab
Fusion protein
Futibatinib
Futuximab
GBR-900
GFRα1
GFRα2
GFRα3
GFRα4
GZ-389988
Galcanezumab
Gambogic amide
Ganitumab
Gantenerumab
Gastrointestinal perforation
Gefitinib
Gemtuzumab ozogamicin
Genentech
Gilteritinib
Glasdegib
Glia maturation factor
Glial cell line-derived neurotrophic factor
Glioblastoma
Glioblastoma multiforme
Glofitamab
Glucose-6-phosphate isomerase
Glypromate
Golvatinib
Gossypetin
Grandinin
Growth factor
Growth factor receptor
HER2/neu
HER3
HER4
HIOC
Hdl (identifier)
Health Canada
Hedgehog signaling pathway
Heparin-binding EGF-like growth factor
Hepatocellular carcinoma
Hepatocyte growth factor
Hepatocyte growth factor receptor
Hepatoma-derived growth factor
Human musculoskeletal system
Humanized
Humanized antibody
Hypertension
IGF-1 LR3
IGFBP1
IGFBP2
IGFBP3
IGFBP4
IGFBP5
IGFBP6
IGFBP7
INCB28060
ISBN (identifier)
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Icrucumab
Idarucizumab
Idelalisib
Imatinib
Imgatuzumab
Immunoglobulin heavy chain
Immunoglobulin light chain
Inavolisib
Inclacumab
Indium (111In) biciromab
Indium (111In) imciromab
Industrial fermentation
Infigratinib
Inotuzumab ozogamicin
Insulin
Insulin-like growth factor-binding protein
Insulin-like growth factor 1
Insulin-like growth factor 1 receptor
Insulin-like growth factor 2
Insulin-like growth factor 2 receptor
Interleukin
Interleukin 2
Intravenous therapy
Intravitreal administration
Intravitreal injection
Ipilimumab
Isatuximab
Isopropanol
JNJ-38877605
Janus kinase
Judah Folkman
K252a
KEGG
KRAS
Keratinocyte growth factor
Kidney cancer
LEVI-04
LM22A-4
Landogrozumab
Lapatinib
Larotrectinib
Lazertinib
Lecanemab
Lenvatinib
Lestaurtinib
Leukemia
Leukemia inhibitory factor
Liatermin
Linsitinib
List of withdrawn drugs
Loncastuximab tesirine
Lorlatinib
Low-affinity nerve growth factor receptor
Lung cancer
Lymphatic system
Lymphoma
MEDI-578
MEN1
MK-2461
MTOR inhibitor
Macrophage-stimulating protein
Marstacimab
Masitinib
Matuzumab
Mecasermin
Mecasermin rinfabate
Medicines and Healthcare products Regulatory Agency
MedlinePlus
Midkine
Midostaurin
Migration-stimulating factor
Milciclib
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody
Monoclonal antibody therapy
Mosunetuzumab
Motesanib
Mouse
Moxetumomab pasudotox
Mubritinib
Murodermin
Myeloid
N-Acetylserotonin
NICE
NRG2
NRG3
NRG4
NVP-ADW742
NVP-AEW541
Napoleone Ferrara
Nasal septum perforation
National Comprehensive Cancer Network
National Health Service
Naxitamab
Necitumumab
Necrotizing fasciitis
Nephrotic syndrome
Nepidermin
Neratinib
Nerve growth factor
Nesvacumab
Neuregulin
Neuregulin-1
Neurology
Neurotrophin-3
Neurotrophin-4
Neurturin
Nilotinib
Nimotuzumab
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Non-small-cell lung carcinoma
Norwogonin
Nose bleeds
ONO-4474
ONO-5390556
OSl-906
Obinutuzumab
Odronextamab
Ofatumumab
Off-label use
Olaparib
Olaratumab
Olmutinib
Onartuzumab
Oncomodulin
Ophthalmology
Opicinumab
Oportuzumab monatox
Orelabrutinib
Orticumab
Osimertinib
Ovarian cancer
Ozanezumab
PDGFA
PDGFB
PDGFC
PDGFD
PF-04217903
PF-2341066
PHA-665752
PLX-7486
PMC (identifier)
PMID (identifier)
Paclitaxel
Pacritinib
Palbociclib
Palifermin
Pancreatic cancer
Panitumumab